{
 "name": "浩宇生醫",
 "slug": "tw-6872",
 "aliases": [
  "浩宇生醫股份有限公司",
  "NaviFUS",
  "6872"
 ],
 "ticker": "6872",
 "industry": "生技醫療業",
 "website": "https://navifus.com/",
 "summary": "浩宇生醫（6872）是上櫃的生技醫療類股公司，2015 年成立，2025 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "浩宇生醫股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "NaviFUS",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2025-03-07",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2015-03-12",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "龍震宇",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "龍震宇",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 707505110,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "https://navifus.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 815,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不符合本次白名單；回查官方115年09月營收申報，claim/value/unit/as_of保留，僅更正輸出複本source。核對列與原來源保存在research/basic_source_corrections.json。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 22.56,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不符合本次白名單；回查官方115年09月營收申報，claim/value/unit/as_of保留，僅更正輸出複本source。核對列與原來源保存在research/basic_source_corrections.json。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 183.26,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不符合本次白名單；回查官方115年09月營收申報，claim/value/unit/as_of保留，僅更正輸出複本source。核對列與原來源保存在research/basic_source_corrections.json。"
  },
  {
   "claim": "管線：NaviFUS＋bevacizumab（Avastin）（NCT06496971）",
   "value": "復發性膠質母細胞瘤｜第三期樞紐試驗；招募中｜台灣",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06496971",
   "note": "NCT06496971；登錄狀態RECRUITING；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  },
  {
   "claim": "催化劑：NaviFUS（NCT06496971）",
   "value": "主要終點完成（試驗登錄預估）｜2026-12-31｜已公告",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06496971",
   "note": "NCT06496971；ClinicalTrials.gov primaryCompletionDateStruct，type=ESTIMATED。登錄者預估，可變動；不是承諾公告結果或核准上市日期。"
  },
  {
   "claim": "催化劑：NaviFUS（NCT06496971）",
   "value": "試驗完成（試驗登錄預估）｜2027-03-31｜已公告",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06496971",
   "note": "NCT06496971；ClinicalTrials.gov completionDateStruct，type=ESTIMATED。登錄者預估，可變動；不是承諾公告結果或核准上市日期。"
  },
  {
   "claim": "管線：NaviFUS（神經調控）（NCT06492720）",
   "value": "頑性癲癇｜先導性醫材試驗；招募中｜台灣",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06492720",
   "note": "NCT06492720；登錄狀態RECRUITING；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  },
  {
   "claim": "催化劑：NaviFUS（NCT06492720）",
   "value": "主要終點完成（試驗登錄預估）｜2026-12-31｜已公告",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06492720",
   "note": "NCT06492720；ClinicalTrials.gov primaryCompletionDateStruct，type=ESTIMATED。登錄者預估，可變動；不是承諾公告結果或核准上市日期。"
  },
  {
   "claim": "催化劑：NaviFUS（NCT06492720）",
   "value": "試驗完成（試驗登錄預估）｜2027-03-31｜已公告",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06492720",
   "note": "NCT06492720；ClinicalTrials.gov completionDateStruct，type=ESTIMATED。登錄者預估，可變動；不是承諾公告結果或核准上市日期。"
  },
  {
   "claim": "管線：NaviFUS（神經調控）（NCT06388707）",
   "value": "藥物難治型癲癇｜第一／二期；招募中｜美國",
   "unit": "",
   "as_of": "2026-09-15",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06388707",
   "note": "NCT06388707；登錄狀態RECRUITING；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  },
  {
   "claim": "催化劑：NaviFUS（NCT06388707）",
   "value": "主要終點完成（試驗登錄預估）｜2027-06-30｜已公告",
   "unit": "",
   "as_of": "2026-09-15",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06388707",
   "note": "NCT06388707；ClinicalTrials.gov primaryCompletionDateStruct，type=ESTIMATED。登錄者預估，可變動；不是承諾公告結果或核准上市日期。"
  },
  {
   "claim": "催化劑：NaviFUS（NCT06388707）",
   "value": "試驗完成（試驗登錄預估）｜2027-10-31｜已公告",
   "unit": "",
   "as_of": "2026-09-15",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06388707",
   "note": "NCT06388707；ClinicalTrials.gov completionDateStruct，type=ESTIMATED。登錄者預估，可變動；不是承諾公告結果或核准上市日期。"
  },
  {
   "claim": "管線：NaviFUS＋bevacizumab（Avastin）（NCT06329570）",
   "value": "復發性膠質母細胞瘤｜第一／二期；暫停（FDA reviewing）｜美國",
   "unit": "",
   "as_of": "2026-09-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06329570",
   "note": "NCT06329570；登錄狀態SUSPENDED；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  },
  {
   "claim": "管線：NaviFUS（神經調控）（NCT05947656）",
   "value": "藥物難治型癲癇｜醫材臨床試驗；招募中｜澳洲",
   "unit": "",
   "as_of": "2026-09-10",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05947656",
   "note": "NCT05947656；登錄狀態RECRUITING；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  },
  {
   "claim": "催化劑：NaviFUS（NCT05947656）",
   "value": "主要終點完成（試驗登錄預估）｜2027-06-01｜已公告",
   "unit": "",
   "as_of": "2026-09-10",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05947656",
   "note": "NCT05947656；ClinicalTrials.gov primaryCompletionDateStruct，type=ESTIMATED。登錄者預估，可變動；不是承諾公告結果或核准上市日期。"
  },
  {
   "claim": "管線：NaviFUS＋bevacizumab（Avastin）（NCT04446416）",
   "value": "復發性膠質母細胞瘤｜先導性醫材試驗已完成（歷史）｜台灣",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04446416",
   "note": "NCT04446416；登錄狀態COMPLETED；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  },
  {
   "claim": "管線：NaviFUS＋再照射（NCT04988750）",
   "value": "復發性膠質母細胞瘤｜醫材安全性及初步療效試驗已完成（歷史）｜台灣",
   "unit": "",
   "as_of": "2026-04-13",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04988750",
   "note": "NCT04988750；登錄狀態COMPLETED；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  },
  {
   "claim": "管線：NaviFUS（神經調控）（NCT04999046）",
   "value": "藥物難治型癲癇｜醫材隨機假治療對照試驗已完成（歷史）｜台灣",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04999046",
   "note": "NCT04999046；登錄狀態COMPLETED；as_of採Last Update Posted。單一登錄試驗狀態，不代表醫材已取得上市許可。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6872.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}